RVLP News and Press, RVL Pharmaceuticals plc From 08/14/23

2023-08-14 06:54:42 ET RVL Pharmaceuticals plc press release ( NASDAQ: RVLP ): Q2 GAAP EPS of -$0.24 misses by $0.12 . Revenue of $8.26M (-2.2% Y/Y) misses by $1.99M . At June 30, 2023, the Company had cash and cash equivalents of $19.2 million and senior secur...

-- UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity -- -- Executed financing amendment with Athyrium, which, subject to certain conditions, would provide meaningful f...

BRIDGEWATER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today...

BRIDGEWATER, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company organized in Ireland focused on the commercialization of UPNEEQ ® (oxymetazoline hydrochloride ophthalmic s...

BRIDGEWATER, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the proposal to approve a waiver of offer obligations under Rule 9 of the Irish Takeover...

2023-05-11 16:29:08 ET RVL Pharmaceuticals plc (RVLP) Q1 2023 Earnings Conference Call May 11, 2023 08:30 AM ET Company Participants Lisa Wilson - In-Site Communications Brian Markison - Chief Executive Officer James Schaub - Chief Operating Officer Michael D...

2023-05-11 06:51:57 ET RVL Pharmaceuticals plc press release ( NASDAQ: RVLP ): Q1 GAAP EPS of -$0.12 in-line. Revenue of $8.83M (-58.7% Y/Y) misses by $0.37M . For further details see: RVL Pharmaceuticals plc GAAP EPS of -$0.12 in-line, revenue of $8.83M miss...

-- First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million -- -- Enhanced operating leverage with a 32%, or $7.9 million, reduction in first quarter 2023 total operating expenditures from the prior year -- -- Majori...

BRIDGEWATER, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today ...

BRIDGEWATER, N.J., April 03, 2023 (GLOBE NEWSWIRE) --  RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”) announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner ...